Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes

Sanofi's Tzield received FDA approval for pediatric type 1 diabetes stage 3, reducing C-peptide decline to 0.13 pmol/mL vs placebo in a 328-patient trial. The therapy advances autoimmune diabetes treatment, expanding disease-modifying options for children and adolescents.